1. Home
  2. VIVS vs MBIO Comparison

VIVS vs MBIO Comparison

Compare VIVS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

N/A

Current Price

$0.28

Market Cap

3.8M

Sector

Health Care

ML Signal

N/A

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.52

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VIVS
MBIO
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8M
4.1M
IPO Year
2010
2023

Fundamental Metrics

Financial Performance
Metric
VIVS
MBIO
Price
$0.28
$0.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
619.2K
16.3K
Earning Date
06-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
$4,603,000.00
N/A
Revenue This Year
$42.38
N/A
Revenue Next Year
$15.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.82
N/A
52 Week Low
$0.26
$0.51
52 Week High
$4.98
$1.84

Technical Indicators

Market Signals
Indicator
VIVS
MBIO
Relative Strength Index (RSI) 33.99 39.53
Support Level $0.27 N/A
Resistance Level $0.58 $0.56
Average True Range (ATR) 0.02 0.02
MACD 0.01 -0.00
Stochastic Oscillator 16.83 28.52

Price Performance

Historical Comparison
VIVS
MBIO

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: